Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 14.10.2026       https://research-hub.de/companies/beno-holding-ag

BENO is strengthening its funding base for the next phase of portfolio expansion. The company plans to raise up to EUR 4.4m through a rights issue at EUR 6.50 per share, with proceeds earmarked for acquisitions. Separately, five property financings totalling c. EUR 28m over the past twelve months generated c. EUR 16m of additional free liquidity. Part of this has already funded the repayment of a EUR 10m bond and further growth, while management sees the remaining liquidity supporting investments and acquisitions of c. EUR 25-30m. Together, these measures improve BENO’s capacity to pursue opportunities in the fragmented German light-industrial and warehouse market. We view the developments positively, although the proposed c. 20% increase in the share count raises the importance of disciplined capital deployment. We reiterate our BUY rating with unchanged PT of EUR 14.00, seeing significant upside potential. The full update can be downloaded under https://research-hub.de/companies/beno-holding-ag
Tue, 13.10.2026       Cantourage Group SE

Company Name: Cantourage Group SE ISIN: DE000A3DSV01   Reason for the research: Update Recommendation: Kaufen from: 13.10.2026 Target price: €11 Target price on sight of: 12 Monate Last rating change: - Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu Cantourage Group SE (ISIN: DE000A3DSV01) ver [ … ]
Tue, 13.10.2026       https://research-hub.de/companies/brenntag-se

We expect Brenntag's Q3 operating EBITDA to decline c.17% sequentially to EUR 385m as exceptional pricing benefits gradually fade, while underlying volumes remain broadly stable. Ongoing cost savings and improving commercial execution, particularly in Specialties, should partly cushion the decline, although higher operating costs remain an offset. Meanwhile, the expected reversal of Q2's price-driven working-capital build should support an FCF recovery in H2. Looking into Q4, a strengthening US dollar could provide a tailwind, partly offsetting pricing normalization. At c.7x 2027E EV/operating EBITDA, valuation remains below our c.8x fair multiple, but a rerating from here would require clearer evidence of volume acceleration and structural margin gains. We maintain our EUR 65.00 price target and HOLD rating. The full update can be downloaded under https://research-hub.de/companies/brenntag-se
Tue, 13.10.2026       https://research-hub.de/companies/lm-pay-sa

LM PAY reported final FY25 and final H1 26 figures. FY25 EBIT rose 77.4% yoy to PLN 12.4m, although financing costs and taxes resulted in a PLN 1.3m net loss. H1 26 EBIT nearly doubled to PLN 7.8m, benefiting from a PLN 1.9m one-off gain. Adjusted EBIT reached c. PLN 5.9m, confirming operating leverage. However, financial expenses surged 53.2%, limiting net profit to PLN 0.5m. Given H1 revenue growth of just 14.2% and ambitious management expectations for H2, we lower our estimates. We reiterate BUY with a revised EUR 56.00 price target (previously EUR 59.00). The full update can be downloaded under https://research-hub.de/companies/lm-pay-sa
Tue, 13.10.2026       https://research-hub.de/companies/formycon-ag

Formycon's FYB206 has become the first publicly disclosed Keytruda biosimilar accepted for FDA review, marking an important regulatory milestone and triggering a payment from US partner Zydus. The achievement strengthens Formycon's first-mover position and provides greater visibility on FY26 guidance, although FYB202's expected H2 recovery remains a key uncertainty. Beyond the near-term financial impact, FYB206 remains Formycon's key pipeline asset and a major driver of future growth. We reiterate BUY and our EUR 38.00 PT. For more insights into Formycon’s FYB206 opportunity, join our virtual roundtable with CEO Stefan Glombitza and CFO Enno Spillner on 21 October. Registration: https://research-hub.de/events/registration/2026-10-21-10-00/FYB-GR The full update can be downloaded under https://research-hub.de/companies/formycon-ag
Tue, 13.10.2026       https://research-hub.de/companies/fraport-ag

Fraport reported a 1.6% yoy increase in Frankfurt passenger numbers in September, though YTD traffic remains more than 12% below 2019 levels. While international assets delivered robust growth and geographic diversification, a cautious stance is warranted due to excess capacity and fixed costs following the Terminal 3 opening. We maintain our EUR 62.00 price target and HOLD rating. The full update can be downloaded under https://research-hub.de/companies/fraport-ag
Tue, 13.10.2026       https://research-hub.de/companies/aixtron-se

We expect AIXTRON's Q3 results to mark a further step in the photonics-driven earnings recovery, with order intake rising to EUR 220–230m, revenue reaching EUR 180m and EBIT margin improving to around 26%. Beyond the quarter, the focus shifts to 2027, where sustained quarterly bookings above EUR 200m imply annual revenue potential of at least EUR 800m, even without a recovery in power electronics. While AI-driven optical connectivity demand remains strong, scaling the supply chain to convert orders into shipments will be the key execution challenge. A recovery in SiC and GaN could provide additional earnings upside from 2028. At around 19x 2027E EV/EBIT, the valuation already reflects meaningful earnings growth, but we still see further earnings potential not yet fully reflected in the share price. We therefore reiterate our BUY rating and adjust our estimates, resulting in a new price target of EUR 43.00 from EUR 40.00. The full update can be downloaded under https://research-hub.de/companies/aixtron-se
Mon, 12.10.2026       https://research-hub.de/companies/traton-se

Traton reported solid Q3 26 unit sales, rising 10% yoy to 78.9k vehicles, in line with consensus expectations. The rebound was primarily driven by strong US demand and catch-up effects following postponed customer purchases. International Motors led growth with a 48% yoy increase, while Scania and Volkswagen Truck & Bus also recorded gains. MAN remained slightly weaker. Nevertheless, 9M 26 unit sales increased by only 3% yoy, highlighting the still gradual and uneven recovery. We expect Q3 revenue of around EUR 11.8bn, up 13% yoy, and adjusted EBIT of EUR 820m, implying a margin of 6.9%, up 50bps yoy. While ageing US truck fleets support replacement demand, macro uncertainty and geopolitical tensions remain risks. Chinese competition in electric trucks and potential further Volkswagen stake sales could weigh on Traton's valuation. We maintain our SELL rating with a PT of EUR 23.00. The full update can be downloaded under https://research-hub.de/companies/traton-se
Mon, 12.10.2026       https://research-hub.de/companies/nordex-se

Nordex continues to benefit from strong global demand, with Q3 order intake surging 29.5% yoy to 2.81 GW, driven by Türkiye, Germany and the US. Although order growth over 9M 26 was more moderate than in the prior year, stable pricing and a broader geographic footprint offer promising prospects. We expect a strong Q3, with revenue rising 27% yoy to EUR 2.17bn and EBITDA reaching EUR 230m, implying a 10.6% margin. Nordex’s substantial order backlog provides strong revenue visibility and supports further margin expansion through higher capacity utilization and economies of scale. We consider FY26 guidance of EUR 8.2–9.0bn in revenue and an 8–11% EBITDA margin very likely to be achieved, with our estimates in the upper third of both ranges. Looking ahead, the key question is whether international markets can offset a potential slowdown in Europe from 2027. We remain positive on the near-term outlook but cautious about the cycle’s longevity, reiterating our BUY rating with a PT of EUR 44.00. The full update can be downloaded under https://research-hub.de/companies/nordex-se
Mon, 12.10.2026       https://research-hub.de/companies/rubean-ag

Rubean expects to benefit from Germany's planned introduction of mandatory electronic cash registers for businesses with annual revenues exceeding EUR 100,000. The company estimates that 2.0-2.3m businesses could fall within the scope of the new requirements and highlights that its SoftPOS solution already integrates a certified technical security device (TSE) for fiscalization. In our view, the regulatory initiative provides another potential driver for SoftPOS adoption, particularly among smaller merchants seeking cost-efficient, software-based payment solutions. However, the actual addressable market and revenue potential remain uncertain, while the latest government proposal envisages implementation in 2028. We leave our estimates unchanged and reiterate our BUY rating and EUR 10.00 PT. The full update can be downloaded under https://research-hub.de/companies/rubean-ag

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2026 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2026 WEBs Investments ETFs
Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 22.11.2026, Calendar Week 47, 326th day of the year, 39 days remaining until EoY.